De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents.
- Author(s): Kuftinec, Gabriela
- Loehfelm, Thomas
- Corwin, Michael
- Durbin-Johnson, Blythe
- Candido, MarieChristi
- Hluhanich, Rebecca
- Sarkar, Souvik
- et al.
Published Web Locationhttps://doi.org/10.2217/hep-2018-0003
Aim:Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV). Methods:In this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or 'de novo' of HCC in patients with HCV-cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1-9.5%) patients developed de novo HCC which did not differ from historical rates of 3% (p = 0.22). Results:Notably, patients with decompensated cirrhosis had significantly higher rate of de novo HCC (9.3%; 95% CI: 3.12-22.2%; p = 0.04). Conclusion:Our data support the need for continued surveillance for HCC in HCV cirrhotics even after successful therapy.